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Abstract 
Aims. The European Society of Cardiology Heart Failure Long‐Term Registry (ESC‐HF‐LT‐R) was set up 
with the aim of describing the clinical epidemiology and the 1‐year outcomes of patients with heart failure 
(HF) with the added intention of comparing differences between participating countries. 
Methods and results. The ESC‐HF‐LT‐R is a prospective, observational registry contributed to by 211 
cardiology centres in 21 European and/or Mediterranean countries, all being member countries of the ESC. 
Between May 2011 and April 2013 it collected data on 12 440 patients, 40.5% of them hospitalized with 
acute HF (AHF) and 59.5% outpatients with chronic HF (CHF). The all‐cause 1‐year mortality rate was 
23.6% for AHF and 6.4% for CHF. The combined endpoint of mortality or HF hospitalization within 1 year 
had a rate of 36% for AHF and 14.5% for CHF. All‐cause mortality rates in the different regions ranged from 
21.6% to 36.5% in patients with AHF, and from 6.9% to 15.6% in those with CHF. These differences in 
mortality between regions are thought reflect differences in the characteristics and/or management of these 
patients. 
Conclusion. The ESC‐HF‐LT‐R shows that 1‐year all‐cause mortality of patients with AHF is still high while 
the mortality of CHF is lower. This registry provides the opportunity to evaluate the management and 
outcomes of patients with HF and identify areas for improvement. 
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Introduction 
Worldwide, an estimated 26 million people suffer from heart failure (HF).
1
 Acute HF (AHF) is 
a complex, heterogeneous clinical syndrome characterized by a rapid onset of signs and symptoms 
of HF that is often life‐threatening and requires urgent therapy.2,3 The prevalence of chronic HF 
(CHF) is increasing.
1
 In the USA and Europe, HF is responsible for a large proportion of deaths, as 
well as for diverse morbidity that leads to diminished quality of life in affected patients.
4
 Despite 
significant advances in diagnosis and therapy over the past 20 years, HF patients still have a poor 
long‐term prognosis.1,5 The cost of HF health care is high and increasing4 and there has been an 
increase in CHF‐related hospitalizations, reaching more than 1 million per year in both the USA 
and Europe.
1
 In pursuit of optimal care, the management of HF patients should be guided by 
protocols that clinical trial evidence has shown to be beneficial.
5-7
 Registries can help improve care 
by both contributing evidence and monitoring compliance with existing guidelines.  
 
In the past, European surveys or registries of CHF or AHF patients
8,9
 have suffered from a 
number of limitations with regard to the extent to which different countries have been represented 
and the completeness with which patients' clinical histories were captured. Within the 
EURObservational Research Programme of the European Society of Cardiology (ESC), the ESC 
HF Pilot Survey aimed to describe the clinical epidemiology and 1‐year outcomes of CHF and 
AHF outpatients and inpatients, and to validate the performance and quality of its data structures, 
data collection procedures, and organization with a view to the establishment of the present long‐
term registry,
10
 the ESC HF Long‐Term Registry (ESC‐HF‐LT‐R). The ESC‐HF‐LT‐R, which has 
an improved structure and in which all the national cardiology societies belonging to the ESC were 
invited to participate,
10,11
 has as its primary objective the description of both the clinical 
epidemiology of HF outpatients and inpatients in European and Mediterranean countries, and the 
diagnostic and therapeutic processes used in the care of these patients (including the organization 
of HF management programmes). It is a prospective, multicentre, observational registry of patients 
referred to cardiology centres within ESC affiliated countries. The countries currently represented 
are Austria, Bosnia and Herzegovina, Bulgaria, the Czech Republic, Egypt, France, Greece, 
Hungary, Israel, Italy, Latvia, Lithuania, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, 
Spain, Sweden, and Turkey.  
 
The aims of the present study were to assess the 1‐year outcomes of patients with AHF and 
patients with CHF, and to identify prognostic predictors of these outcomes
.10
 
Methods 
Participating centres, study design, and clinical setting 
Each participating country was asked to select a number of cardiac centres approximately 
proportional to the country's population (as close as possible to one centre per two million 
inhabitants), approximately 20% of which should consist of centres providing cardiac surgery, 
30% that do not provide cardiac surgery but do provide interventional cardiology, and 50% 
community centres providing neither cardiac surgery nor interventional cardiology. Participating 
centres enrolled patients in the registry on a one‐day‐per‐week basis. All outpatients with CHF 
seen at the clinics and those admitted to hospital for AHF (either pre‐existing or new‐onset HF) for 
whom intravenous therapy (diuretics, inotropes or vasodilators) was needed, were included. There 
were no specific exclusion criteria, with the exception of age, which had to be greater than 
18 years. Patients were followed up in accordance with the usual practice of the centres, with the 
exception of a mandatory follow‐up visit at 12 months to collect information on morbidity and 
mortality. In cases where the patient was unable to reach the clinical centre, a phone call replaced 
this follow‐up clinical visit. Participation in the ESC‐HF‐LT‐R had been approved by each local 
institutional review board in accordance with its country's legislation. No data were collected 
before the patient received detailed information and gave signed informed consent. Random audits 
were conducted in each participating country. 
 
In this 1‐year follow‐up analysis, patient data of the best 12 consecutive recruitment months for 
each country were used for the analyses. The countries represented in the registry were grouped in 
six geographical regions as follows: Northern Europe (Lithuania and Sweden); Eastern Europe 
(Bosnia and Herzegovina, Bulgaria, the Czech Republic, Hungary, Latvia, Poland, Romania, and 
Slovakia); Western Europe (Austria and France); Southern Europe (Greece, Italy, Portugal, Serbia, 
Slovenia, Spain, and Turkey); the Middle East (Israel); and North Africa (Egypt). 
Statistical analysis 
Descriptive statistics were used to summarize frequency tabulations (n, %) and distributions 
[mean, standard deviation (SD), median, interquartile ranges]. All the results were summarized 
overall and by subgroup populations.  
 
Categorical variables are presented as percentages, while continuous variables are presented as 
means and SD plus median and interquartile range (IQR). Categorical variables were compared by 
the chi‐square test and continuous variables by a non‐parametric test (Kruskal–Wallis test). 
 
Baseline characteristics and type of treatments are also reported stratified by area of enrolment 
(Eastern, Middle East, Northern, North African, Southern, and Western). 
 
Plots of Kaplan–Meier curves for time to all‐cause death and time to all‐cause death or HF 
hospitalization were performed. In addition, these plots were divided into outpatients with CHF 
and inpatients with AHF. Plots of cumulative incidence of HF hospitalization considering 
competing risks of death in the two groups are presented. 
  
All variables at entry that were statistically significant at univariate analysis and variables 
considered of relevant clinical interest were included in the multivariable model (Cox model) to 
identify the independent predictors of all‐cause death from study entry to 1‐year follow‐up, 
separately for AHF and CHF. Age, systolic blood pressure, body mass index (BMI) and ejection 
fraction (EF) were considered as continuous variables while the remaining were considered as 
categorical variables. Analyses were performed with program R (Vienna University of Economics 
and Business Administration, Vienna, Austria) and the package Hmisc (Vanderbilt University, 
Nashville, TN, USA). A P‐value <0.05 was considered statistically significant.  
Results 
Of the 12 785 patients eligible for inclusion in the registry between April 2011 and April 2013, 
12 440 gave informed consent and were included in this study. Of these, 5039 (40.5%) were 
inpatients hospitalized with a diagnosis of AHF and 7401 (59.5%) were outpatients with CHF. At 
1 year, 341 AHF patients had been lost to follow‐up (6.7%), along with 228 CHF patients (3%) 
(Figure 1). The mortality rate during the initial hospitalization event for AHF was 4.9% (249 out 
of 5049).  
 
 
 
Figure 1 European Society of Cardiology (ESC) Heart Failure Long‐term 1‐year follow‐up flow diagram. ‘Inpatients’, 
acute heart failure patients; ‘Outpatients’, chronic heart failure patients; Pts, patients; FU, follow‐up. 
Southern Europe and Turkey contributed 46.7% of the study's patients, Eastern Europe 23.5%, 
North Africa 13%, Northern Europe 6.6%, Western Europe 6.5%, and the Middle East 3.7%. Most 
regions contributed more CHF than AHF patients, but 71% of North African patients and 54% of 
Eastern European patients were AHF patients (Table 1).  
Table 1. Geographic areas and patients included 
Areas Total n = 12 440 AHF n = 5039 CHF n = 7401 
    
Eastern, n (%)  2922 (23.5) 1587 (31.5) 1335 (18.0) 
Northern, n (%)  821 (6.6) 386 (7.7) 435 (5.9) 
Southern, n (%)  5807 (46.7) 1486 (29.5) 4321 (58.4) 
Western, n (%)  810 (6.5) 257 (5.1) 553 (7.5) 
North Africa, n (%)  1613 (13.0) 1145 (22.7) 468 (6.3) 
Middle East, n (%)  467 (3.7) 178 (3.5) 289 (3.9) 
    
 
AHF, acute heart failure; CHF, chronic heart failure. 
Baseline characteristics 
The baseline characteristics of the 4449 AHF and 7173 CHF patients who neither died nor 
were lost to follow‐up, and for whom 1‐year follow‐up data were available, are reported in 
Table 2. Hospitalized (AHF) patients were older than outpatients; a greater percentage of them 
were women (37.4% vs. 28.8%); a smaller percentage had a systolic blood pressure (SBP) 
≤110 mmHg (25.2% vs. 31.0%), and a larger percentage had preserved EF, defined as EF >45% 
(33.4% vs. 23.2%). More than half of AHF patients had an ischaemic aetiology, and 44.2% 
exhibited mitral regurgitation, as against only 25.8% of CHF patients. Common co‐morbidities 
[atrial fibrillation, diabetes mellitus, hypertension and chronic obstructive pulmonary disease 
(COPD)] were more frequent among AHF patients, as also were smoking (16% vs. 11.2%), 
hyponatraemia (sodium <135 mEq/L in 19.5% and <130 mEq/L in 5.42% vs. 8.23% and 1.14%, 
respectively, among CHF patients) and hyperkalaemia (potassium >5.5 mEq/L in 4.44% vs. 
2.64%). Pulmonary and/or peripheral congestion was present in 84.8% of AHF and 74.4% of CHF 
patients.  
 
Patient's demographic and baseline characteristics in the individual regions are summarized in 
Table 3 for CHF patients and in Table 4 for AHF patients. For CHF patients there were significant 
between‐region differences. North African patients were younger than those of other regions, had 
higher heart rates, a greater percentage were women, a greater percentage smoked. In addition, 
preserved EF, hyponatraemia and SBP ≤110 mmHg were all more frequent, while both 
angiotensin‐converting enzyme inhibitors (ACEI)/angiotensin receptor antagonists (ARBs) and 
beta‐blockers were used less frequently. Middle Eastern and North European patients were older 
than those of other regions and greater percentages had an ischaemic aetiology (59.1% and 48.0%, 
respectively). Alcohol consumption was most prevalent among North European patients. The use 
of implantable devices was also quite different: implantable cardioverter defibrillators (ICDs) or 
cardiac resynchronization therapy with defibrillation (CRT‐D) were used by 21.3% of West 
European patients, 20.6% of Middle Eastern patients, and 18.5% of South European patients 
compared with only 0.2% of North African patients (Table 3). 
Table 2. Demographics and other basal characteristics of the study population completing the 1‐year follow‐up 
 
AHF n = 4449 CHF n = 7173 P‐value 
    
Age (years)    
Mean ± SD 69.35 ± 12.98 64.89 ± 13.30 <0.0001 
Median [IQR] 71 [61–79] 66 [57–75] <0.0001 
≥75 years, % 38.9 26.0 <0.0001 
Females, % 37.4 28.8 <0.0001 
BMI (kg/m2)     
Mean ± SD 28.67 ± 5.39 28.10 ± 5.04 <0.0001 
Median [IQR] 28 [25–31] 28 [25–31] <0.0001 
SBP (mmHg)    
Mean ± SD 133.45 ± 28.17 123.78 ± 20.73 <0.0001 
Median [IQR] 130 [110–150] 120 [110–136] <0.0001 
≤110 mmHg, % 25.2 31.0 <0.0001 
Heart rate (bpm)    
Mean ± SD 90.82 ± 25.27 72.70 ± 15.29 <0.0001 
Median [IQR] 88 [73–102] 70 [62–80] <0.0001 
≥70 bpm, % 82.7 55.2 <0.0001 
Ejection fraction (%)    
Mean ± SD (available for 9198 patients) 
Median [IQR] (available for 9198 patients) 
>45%, % 
>40%, % 
>50%, % 
40.42 ± 14.89 
39.00 [30–52] 
33.4 
41.6 
25.7 
37.21 ± 13.62 
35.00 [28–45] 
23.2 
33.2 
16.3 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
NYHA III–IV, % 85.2 25.2 <0.0001 
Pulmonary or peripheral congestion, % 84.8 74.4 <0.0001 
Third heart sound, % 31.8 5.6 <0.0001 
Peripheral hypoperfusion/cold, % 14.9 3.4 <0.0001 
Mitral regurgitation, % 44.2 25.8 <0.0001 
Aortic stenosis, % 8.9 3.9 <0.0001 
Alcohol, % 33.2 32.4 0.60 
Smoking, % 16.0 11.2 <0.0001 
Sodium    
<135 mEq/L, % 
<130 mEq/L, % 
19.5 
5.42 
8.23 
1.14 
<0.0001 
<0.0001 
Potassium    
>5.5 mEq/L, % 
>6 mEq/L, % 
4.44 
1.44 
2.64 
0.455 
<0.0001 
<0.0001 
Heart failure history with previous hospitalization, % 
Heart failure history without previous hospitalization, % 
New‐onset heart failure 
30.3 
40.6 
29.1 
41.1 
48.9 
10.0 
<0.0001 
Heart failure diagnosis >12 months, % 54.8 64.2 <0.0001 
Ischaemic heart disease, % 53.8 43.1 <0.0001 
Atrial fibrillation, % 44.0 37.7 <0.0001 
Diabetes mellitus, % 39.0 31.9 <0.0001 
PAD, % 13.7 12.4 0.04 
Hypertension, % 65.6 58.3 <0.0001 
COPD, % 20.1 13.9 <0.0001 
Sleep apnoea, % 3.2 5.3 <0.0001 
Previous stroke/TIA, % 12.5 9.5 <0.0001 
Renal dysfunction, % 25.3 18.4 <0.0001 
Hepatic dysfunction, % 7.7 3.4 <0.0001 
Depression, % 7.4 7.7 0.65 
PM, % 6.4 5.8 0.28 
    
 
AHF, acute heart failure; CHF, chronic heart failure; SD, standard deviation; IQR, interquartile range; BMI, body mass 
index; SBP, systolic blood pressure; NYHA, New York Heart Association; PAD, peripheral artery disease; COPD, chronic 
obstructive pulmonary disease; TIA, transient ischaemic attack; PM, pacemaker. 
Table 3. Comparison of baseline and demographic characteristics among regions. Chronic heart failure patients who completed the 1‐year follow‐up 
Characteristics Easternn = 1290 Middle Eastn = 286 Northernn = 421 North Africann = 414 Southernn = 4248 Westernn = 514 P‐value 
        
Age (years)        
Mean ± SD 
Median [IQR] 
≥75 years, % 
64.21 ± 13.31 
65 [57–74] 
23.3 
68.02 ± 12.28 
68 [60–78] 
32.2 
67.76 ± 13.29 
70 [60–79] 
35.9 
55.32 ± 13.48 
58 [47–65] 
4.3 
65.87 ± 12.74 
67 [58–76] 
28.1 
62.04 ± 14.30 
62 [53–72] 
22.0 
<0.0001 
<0.0001 
<0.0001 
Females, % 27.2 25.2 31.1 34.8 28.9 26.5 0.02 
Ischaemic aetiology, % 47.4 59.1 48.0 44.7 41.4 32.7 <0.0001 
BMI (kg/m2)         
Mean ± SD 
Median [IQR] 
28.58 ± 5.15 
28 [25–31] 
29.37 ± 5.69 
28 [25–33] 
28.6 ± 5.71 
28 [25–32] 
28.69 ± 5.50 
28 [25–31] 
27.89 ± 4.83 
28 [25–31] 
27.24 ± 5.28 
27 [24–30] 
<0.0001 
<0.0001 
SBP (mmHg)        
Mean ± SD 
Median [IQR] 
≤110 mmHg, % 
126.00 ± 20.06 
125 [110–140] 
26.1 
125.03 ± 18.83 
124 [111–136] 
23.4 
129.66 ± 22.94 
130 [115–142] 
22.6 
124.44 ± 27.13 
120 [110–133] 
41.5 
122.84 ± 19.95 
120 [110–135] 
32.1 
119.84 ± 20.37 
120 [106–130] 
37.2 
<0.0001 
<0.0001 
<0.0001 
Heart rate (bpm)        
Mean ± SD 
Median [IQR] 
≥70 bpm, % 
74.81 ± 15.41 
72 [65–80] 
63.2 
72.74 ± 13.02 
71 [64–80] 
55.9 
72.97 ± 16.06 
70 [62–80] 
52.9 
92.09 ± 16.42 
90 [80–100] 
94.9 
70.59 ± 13.93 
70 [60–77] 
50.6 
68.94 ± 13.27 
67 [60–76] 
42.2 
<0.0001 
<0.0001 
<0.0001 
Ejection fraction, %        
Mean ± SD (available for 6370 patients) 34.99 ± 12.60 35.61 ± 14.28 32.20 ± 12.62 41.21 ± 13.67 38.24 ± 13.79 34.29 ± 12.69 <0.0001 
Median [IQR] (available for 6370 patients) 34 [25–43] 30 [25–43] 30 [25–41] 39 [30–48] 36 [29–46] 33 [25–40] <0.0001 
>45%, % 18.4 19.6 17.5 28.1 25.8 13.5 <0.0001 
>40%, % 26.8 25.3 25.2 40.2 36.8 21.7 <0.0001 
>50%, % 11.0 17.5 9.8 21.9 18.5 9.3 <0.0001 
Hypertension, % 65.0 71.3 59.9 41.5 58.6 44.0 <0.0001 
Diabetes, % 30.6 52.1 20.7 33.1 33.1 22.4 <0.0001 
Smoking, % 10.0 15.0 13.2 25.8 8.9 17.7 <0.0001 
Alcohol, % 46.4 28.3 77.0 2.4 27.6 44.1 <0.0001 
Hyponatraemia        
<135 mEq/L, % 9.2 6.0 6.5 35.9 5.9 7.6 <0.0001 
<130 mEq/L, % 1.4 0.4 1.4 5.9 0.7 1.0 <0.0001 
Elevated serum potassium        
>5.5 mEq/L, % 1.9 2.5 1.3 1.8 3.2 1.4 0.0322 
>6 mEq/L, % 0.4 0.0 0.5 0.0 0.6 0.0 0.3954 
History of atrial fibrillation, % 42.2 41.3 47.9 23.2 36.4 37.9 <0.0001 
ACEI/ARBs, % 90.0 85.0 85.5 71.3 84.3 93.2 <0.0001 
Beta‐blockers, % 90.8 91.6 82.8 48.3 84.8 92.2 <0.0001 
Table 3. Comparison of baseline and demographic characteristics among regions. Chronic heart failure patients who completed the 1‐year follow‐up 
Characteristics Easternn = 1290 Middle Eastn = 286 Northernn = 421 North Africann = 414 Southernn = 4248 Westernn = 514 P‐value 
Aldosterone blockers, % 62.2 38.8 51.0 50.2 53.3 48.4 <0.0001 
ICD, % 14.2 20.6 4.5 0.2 18.5 21.3 <0.0001 
CRT‐P, % 3.5 2.1 3.8 0.0 2.1 2.3 0.0006 
CRT‐D, % 15.8 19.2 5.0 0.2 10.5 14.3 <0.0001 
        
 
AHF, acute heart failure; CV, cardiovascular; HF, heart failure; CHF, chronic heart failure. 
 
  
Table 4. Comparison of baseline and demographic characteristics among regions. Acute heart failure patients who completed the 1‐year follow‐up 
Characteristics Easternn = 1429 Middle Eastn = 167 Northernn = 346 North Africann = 960 Southernn = 1305 Westernn = 242 P‐value 
        
Age (years),        
Mean ± SD 
Median [IQR], 
≥75, % 
68.90 ± 12.37 
70 [61–78] 
36.5 
75.11 ± 11.88 
77 [70–84] 
59.3 
73.65 ± 12.59 
76 [67–83] 
54.0 
61.64 ± 11.93 
62 [56–70] 
12.4 
72.71 ± 11.78 
75 [66–81] 
51.0 
74.39 ± 13.65 
77 [66–85] 
57.0 
<0.0001 
<0.0001 
<0.0001 
Females, % 37.8 43.1 38.7 29.7 41.0 40.5 <0.0001 
Ischaemic aetiology, % 53.8 54.5 51.0 68.3 46.7 38.0 <0.0001 
BMI, kg/m2        
Mean ± SD 
Median [IQR] 
28.50 ± 5.55 
28 [25–31] 
29.39 ± 5.24 
29 [26–32] 
30.04 ± 4.92 
29 [26–33] 
29.84 ± 5.00 
29 [26–33] 
28.06 ± 5.12 
27 [25–31] 
27.45 ± 6.56 
27 [24–30] 
<0.0001 
<0.0001 
SBP (mmHg)        
Mean ± SD 
Median [IQR] 
≤110, % 
132.87 ± 27.98 
130 [115–150] 
23.9 
142.30 ± 27.33 
140 [125–161] 
12.6 
136.63 ± 30.62 
130 [120–150] 
15.5 
134.00 ± 30.43 
130 [110–150] 
30.5 
132.57 ± 26.34 
130 [111–150] 
24.9 
132.31 ± 28.40 
130 [111–150] 
24.8 
0.0006 
0.0006 
<0.0001 
Heart rate (bpm)        
Mean ± SD 
Median [IQR] 
≥70, % 
87.09 ± 24.78 
80 [70–100] 
79.3 
85.65 ± 20.72 
81 [71–97] 
79.0 
85.42 ± 24.70 
80 [68–98] 
69.0 
102.38 ± 21.60 
100 [90–110] 
97.0 
88.45 ± 26.07 
83 [70–100] 
78.9 
84.95 ± 26.52 
78 [68–98] 
73.1 
<0.0001 
<0.0001 
<0.0001 
Ejection fraction, %        
Mean ± SD (available for 2828 patients) 37.34 ± 14.32 44.06 ± 14.16 36.29 ± 13.10 38.43 ± 12.31 44.55 ± 16.18 41.54 ± 16.29 <0.0001 
Median [IQR] (available for 2828 patients) 35 [25–50] 43 [30–60] 38 [26–47] 35 [30–44] 45 [30–60] 42 [30–55] <0.0001 
Ejection fraction        
>45%, % 
>40%, % 
>50%, % 
28.5 
36.7 
19.2 
44.2 
51.0 
38.8 
26.3 
44.7 
10.5 
19.8 
29.2 
15.0 
46.4 
53.4 
38.4 
41.6 
50.9 
32.3 
<0.0001 
<0.0001 
<0.0001 
Hypertension, % 70.3 91.0 62.8 45.6 71.5 71.1 <0.0001 
Diabetes, % 36.6 55.7 31.8 45.5 38.5 29.8 <0.0001 
Smoking, % 12.6 19.8 14.0 26.4 13.3 9.5 <0.0001 
Alcohol, % 44.8 45.5 75.4 1.0 37.7 28.9 <0.0001 
Hyponatraemia        
<135 mEq/L, % 
< 130 mEq/L, % 
17.0 
3.4 
14.0 
4.2 
23.0 
8.1 
24.0 
8.2 
17.0 
3.6 
18.0 
5.8 
0.0015 
<0.0001 
Elevated serum potassium        
>5.5 mEq/L, % 
>6 mEq/L, % 
4.8 
1.7 
4.3 
0.6 
6.1 
1.5 
2.1 
1.0 
4.2 
1.2 
4.2 
1.7 
0.0289 
0.6201 
History of atrial fibrillation, % 46.8 49.1 61.0 24.8 49.0 49.6 <0.0001 
ACEI/ARBs, % 66.7 60.5 80.3 68.1 62.7 66.8 0.0043 
Beta‐blockers, % 69.4 73.0 80.3 34.3 51.0 63.9 <0.0001 
Table 4. Comparison of baseline and demographic characteristics among regions. Acute heart failure patients who completed the 1‐year follow‐up 
Characteristics Easternn = 1429 Middle Eastn = 167 Northernn = 346 North Africann = 960 Southernn = 1305 Westernn = 242 P‐value 
Aldosterone blockers, % 40.5 12.0 45.1 41.5 27.0 19.9 <0.0001 
ICD, % 8.6 3.6 5.2 0.1 4.5 6.8 <0.0001 
CRT‐P, % 1.0 0.0 0.9 0.2 0.4 1.3 0.05 
CRT‐D, % 4.2 7.2 6.4 0.0 2.5 6.0 <0.0001 
        
 
SD, standard deviation; IQR, interquartile range; BMI, body mass index; SBP, systolic blood pressure; ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ICD, implantable cardioverter 
defibrillator CRT‐P, cardiac resynchronization therapy with pacemaker; CRT‐D, cardiac resynchronization therapy with defibrillation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Generally similar between‐region differences in baseline characteristics and treatment were 
found among AHF patients. North African patients were younger than others (only 12.4% were 
75 years or older, compared with 36.5% in Eastern Europe, and more than 50% in the other 
regions); they had higher heart rates, and ischaemic aetiology, smoking and SBP ≤110 mmHg 
were all more frequent. In contrast, with a rate of 19.8%, preserved EF was less frequent among 
North African patients than among others. Diabetes and hypertension were more frequent among 
Middle Eastern patients than among others, while the highest rates of alcohol consumption and 
atrial fibrillation were found among North European patients (Table 4).  
Follow‐up 
Owing to between‐country differences in the starting date of enrolment, there were varying 
follow‐up times in the entire study group: median follow‐up time was 373 days, with 9.7% having 
more than 2 years' follow‐up. Figure 2 shows the Kaplan–Meier curves for all‐cause mortality in 
AHF and in CHF patients, Figure 3 shows the cumulative incidence curves for hospitalization for 
HF, and Figure 4 shows the Kaplan‐Meier curves for the combined event of all‐cause mortality or 
hospitalization for HF. The all‐cause 1‐year mortality rate was 23.6% among AHF patients [95% 
confidence interval (CI) 22.4–24.8%], and 6.4% among CHF patients (95% CI 5.8–6.9%). The 
corresponding figures for HF hospitalization were 18.7% (95% CI 17.5–19.9%) and 9.9% (95% CI 
9.2–10.6%), respectively, while the rates of the combined event (death or hospitalization for HF) 
were 36% among AHF patients (95% CI 34.6–37.4%) and 14.5% among CHF patients (95% CI 
13.6–15.3%).  
 
 
 
Figure 2 Kaplan–Meier curves for all‐cause mortality in acute heart failure and chronic heart failure patients. 
  
 
 
 
Figure 3 Cumulative incidence plots of heart failure (HF) hospitalization in acute heart failure and chronic heart failure 
patients. 
 
 
 
Figure 4 Kaplan–Meier curves for the combined event of all‐cause mortality and heart failure (HF) hospitalization in acute 
heart failure and chronic heart failure patients. 
Table 5 reports statistics on mortality, causes of death, and hospitalization rates. Among all 
AHF patients, 51.7% of all deaths were attributed to cardiovascular causes and 13.7% to non‐
cardiovascular causes, while no causal attribution was made in 34.7%. Some 37.9% of these 
patients were rehospitalized at least once for some cause, and in 22.2% of these readmissions the 
cause was HF. The incidence of all‐cause death or rehospitalization for HF was 40.1%. 
 
 
  
Table 5. Causes of death of all subjects 
AHF patients 
Total 
n = 5039 
Eastern 
n = 1587 
Middle East 
n = 178 
Northern 
n = 386 
North African 
n = 1145 
Southern 
n = 486 
Western 
n = 257 
P‐value 
         
Mortality, %         
All‐cause 
CV 
Non‐CV 
Unknown 
26.0 
51.7 
13.7 
34.7 
21.6 
56.7 
12.0 
31.3 
27.5 
30.6 
46.9 
22.4 
36.5 
48.2 
25.5 
26.2 
29.1 
37.8 
5.7 
56.5 
24.8 
64.0 
13.6 
22.5 
29.6 
50.0 
13.2 
36.8 
<0.0001 
<0.0001 
Hospitalization, %         
All‐cause 37.9 42.5 72.5 8.7 32.0 38.6 48.4 <0.0001 
HF 22.2 22.2 34.1 3.8 26.9 22.2 21.5 <0.0001 
All‐cause or HF 40.1 36.4 49.4 39.1 45.4 38.3 44.0 <0.0001 
CHF patients n = 7401 n = 1335 n = 289 n = 435 n = 468 n = 4321 n = 553  
Mortality, %         
All‐cause 
CV 
Non‐CV 
Unknown 
8.3 
49.8 
23.2 
27.0 
7.9 
38.7 
17.0 
44.3 
14.9 
23.3 
62.8 
13.9 
11.3 
65.3 
26.5 
8.2 
15.6 
41.1 
17.8 
41.1 
6.9 
54.2 
21.4 
24.4 
7.6 
71.4 
16.7 
11.9 
<0.0001 
<0.0001 
Hospitalization, %         
All‐cause 24.9 30.4 48.6 8.6 10.1 22.7 42.2 <0.0001 
HF 10.9 13.1 21.3 4.0 7.2 10.0 16.1 <0.0001 
All‐cause or HF 16.9 19.3 31.5 14.5 20.3 14.9 18.3 <0.0001 
         
 
AHF, acute heart failure; CV, cardiovascular; HF, heart failure; CHF, chronic heart failure. 
 
Because of the above‐mentioned heterogeneity of follow‐up times, the regional statistics 
presented in Table 5 do not allow meaningful direct comparisons between regions (the percentages 
listed are percentages with respect to all subjects included in the study or all subjects who died 
regardless of their follow‐up times). The influence of region was evaluated in the Cox regression, 
which showed older age, lower SBP, lower EF, geographical region (North African vs. Southern), 
New York Heart Association (NYHA) class III or IV, the presence of pulmonary or peripheral 
congestion, aortic stenosis, non‐ischaemic aetiology, diabetes mellitus, COPD, previous stroke or 
transient ischaemic attack, renal dysfunction, hepatic dysfunction, and use of a CRT pacemaker 
(CRT‐P) or CRT‐D to be independent predictors of 1‐year all‐cause mortality (Table 6). 
  
Table 6. Predictors of all‐cause of mortality in acute heart failure (AHF) patients (multivariable 
analysis) 
Variable: AHF (Hospital) HR (95% CI) P‐value 
   
Age (every 5 years: IQR 55–60) 1.24 (1.19–2.29) <0.0001 
SBP (every 5 mmHg: IQR 110–115) 0.95 (0.94–0.97) <0.0001 
Ejection fraction (every 5%: IQR 30–35) 0.94 (0.91–0.97) <0.0001 
Region (NAfr: S)* 2.71 (2.15–3.41) <0.0001 
NYHA III–IV (yes vs. no) 1.50 (1.11–2.03) 0.0086 
Pulmonary or peripheral congestion (no vs. yes) 0.68 (0.51–0.91) 0.0095 
Aortic stenosis (yes vs. no) 1.54 (1.24–1.92) 0.0001 
Ischaemic aetiology (yes vs. no) 0.68 (0.58–0.79) <0.0001 
Diabetes mellitus (yes vs. no) 1.20 (1.03–1.39) 0.0192 
COPD (yes vs. no) 1.28 (1.08–1.51) 0.0043 
Previous stroke/TIA (yes vs. no) 1.26 (1.03–1.54) 0.0225 
Renal dysfunction (yes vs. no) 1.52 (1.29–1.78) <0.0001 
Hepatic dysfunction (yes vs. no) 1.57 (1.28–1.93) <0.0001 
CRT‐D (yes vs. no) 1.64 (1.16–2.31) 0.0053 
   
 
HR, hazard ratio; CI, confidence interval; IQR, interquartile range; SBP, systolic blood pressure; 
NYHA, New York Heart Association; COPD, chronic obstructive pulmonary disease; TIA, 
transient ischaemic attack; CRT‐D, cardiac resynchronization therapy with defibrillation. 
* S is the reference. The CI of the other regions compared with S are not significant. P‐value 
refers to the factor region as a whole.  
The total number of death events was 790/3021 (26.2%). 
Among all CHF patients, 49.8% of deaths were of cardiovascular origin, 23.2% of non‐
cardiovascular origin, and 27% of unknown origin (Table 5). The all‐cause hospitalization rate was 
24.9%, and the rate of hospitalization for HF was 10.9%. The incidence of the combined event of 
all‐cause death or hospitalization because of HF was 16.9%. Cox analysis showed older age, lower 
BMI, lower SBP, geographical region (Southern vs. North European), NYHA class III or IV, the 
presence of pulmonary or peripheral congestion, third heart sound, aortic stenosis, atrial 
fibrillation, peripheral vascular disease, renal dysfunction, and absence of ICD implantation to be 
independent predictors of 1‐year all‐cause mortality (Table 7). 
  
Table 7. Predictors of all‐cause of mortality in congestive heart failure (CHF) patients (multivariable analysis) 
Variable: CHF (outpatient) HR (95%CI) P‐value 
   
Age (every 5 years: IQR 55–60) 1.11 (1.04–1.18) 0.0007 
BMI (every 1 kg/m2: IQR 25–26)  0.95 (0.93–0.98) 0.0005 
SBP (every 5 mmHg: IQR 110–115) 0.94 (0.91–0.97) 0.0001 
Region (N: S)*  0.47 (0.25–0.90) 0.0204 
NYHA III–IV (yes vs. no) 1.93 (1.50–2.49) <0.0001 
Pulmonary or peripheral congestion (no vs. yes) 0.39 (0.26–0.60) <0.0001 
Third heart sound (yes vs. no) 1.54 (1.07–2.20) 0.0186 
Aortic stenosis (yes vs. no) 1.70 (1.12–2.59) 0.0135 
Atrial fibrillation (yes vs. no) 1.45 (1.13–1.86) 0.0033 
PAD (yes vs. no) 1.62 (1.19–2.19) 0.0019 
Renal dysfunction (yes vs. no) 1.41 (1.09–1.83) 0.0080 
ICD (yes vs. no) 0.67 (0.46–0.98) 0.0414 
   
 
HR, hazard ratio; CI, confidence interval; IQR, interquartile range; BMI, body mass index; SBP, systolic blood pressure; 
NYHA, New York Heart Association; PAD, peripheral artery disease; ICD, implantable cardioverter defibrillator. 
* S is the reference. The CI of the other regions compared with S are not significant. P‐value refers to the factor region as a 
whole. The total number of death events was 302/2599 (11.6%).  
Pharmacological treatment 
Statistics on the medication prescribed for CHF patients at baseline and 1‐year follow‐up are 
presented in Table 8. At the baseline visit ACEI/ARBs were prescribed for 89.2% of patients, and 
for slightly fewer at the 1‐year follow‐up (86.5%), whereas the percentage of patients treated with 
beta‐blockers increased slightly from 88.9% to 89.1%. Prescription of mineralocorticoid receptor 
antagonists (MRAs) remained essentially stable (59.3% at baseline and 59.1% 1 year later). 
Digitalis prescription fell from 23.0% to 20.9%, prescription of antiplatelet agents from 48.6% to 
47.0%, and prescription of diuretics from 83.1% to 81.2%. However, there were significant 
increases in the prescription of oral anticoagulants (from 42.4% to 43.6%), ivabradine (from 8.4% 
to 10.3%), and amiodarone (from 13.8% to 15.6%). The baseline to 1‐year differences in the 
prescription of statins, nitrates and calcium channel blockers were not statistically significant.  
  
Table 8. Pharmacological treatment of chronic heart failure patients during outpatient visit and at 1 year 
 
During visit At 1 year P‐value 
    
ACEI/ARBs, % 89.2 86.5 <0.0001 
Beta‐blockers, % 88.9 89.1 0.0001 
MRAs, % 59.3 59.1 0.2755 
Diuretics, % 83.1 81.2 <0.0001 
Digitalis, % 23.0 20.9 0.0035 
Statins, % 60.9 63.2 0.2599 
Antiplatelet, % 48.6 47.0 0.0030 
OAC, % 42.4 43.6 0.0253 
Amiodarone, % 13.8 15.6 <0.0001 
Ivabradine, % 8.4 10.3 <0.0001 
Nitrates, % 19.4 18.5 0.6295 
Calcium channel blockers, % 11.3 10.7 0.2044 
    
 
ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, 
mineralocorticoid receptor antagonist; OAC, oral anticoagulation. 
Table 9 shows statistics for the medications prescribed for AHF patients at discharge and at 1‐
year follow‐up. Prescription of ACEI/ARBs rose significantly from 77.0% at discharge to 79.1% 
1 year later, and prescription of MRAs rose from 53.9% to 56.5%, while the use of digitalis fell 
from 25.9% to 23.6%, that of antiplatelet agents fell from 60.8% to 60.5%, that of oral 
anticoagulants fell from 42.7% to 40.7%, that of nitrates from fell 31.9% to 31.0%, and that of 
calcium channel blockers fell from 15.9% to 15.3%. There were no statistically significant 
differences between baseline and 1‐year follow‐up prescription of ivabradine, statins, amiodarone, 
beta‐blockers, or diuretics. 
Table 9. Pharmacological treatment of acute heart failure patients at discharge and at 1 year 
 
At discharge At 1 year P‐value 
    
ACEI/ARBs, % 77.0 79.1 0.0003 
Beta‐blockers, % 72.6 77.8 0.1211 
MRAs, % 53.9 56.5 0.0416 
Diuretics, % 83.9 86.4 0.1735 
Digitalis, % 25.9 23.6 <0.0001 
Statins, % 57.8 62.1 0.1579 
Antiplatelet, % 60.8 60.5 <0.0001 
OAC, % 42.7 40.7 0.0014 
Amiodarone, % 13.6 13.6 0.3097 
Ivabradine, % 3.2 3.1 0.6485 
Nitrates, % 31.9 31.0 <0.0001 
Calcium channel blockers, % 15.9 15.3 <0.0001 
    
 
ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, 
mineralocorticoid receptor antagonist; OAC, oral anticoagulation.  
Discussion 
The ESC‐HF‐LT‐R analysed AHF and CHF patients who were treated at the same hospitals by 
the same physicians and who had been followed up for 1 year. The loss‐to‐follow‐up rate, which is 
overall less than 5%, is acceptable for an observational study and allows confident inference of 
conclusions on clinical evolution, therapies and patient outcomes. The main findings of the study 
are: (i) the all‐cause 1‐year mortality rates in the pool of participating countries were 23.6% for 
AHF and 6.4% for CHF; (ii) the 1‐year rates of hospitalization because of HF were 18.7% for 
AHF and 9.9% for CHF; (iii) the 1‐year incidence rates of the combined event ‘all‐cause mortality 
or HF hospitalization’ were 36% for AHF and 14.5% for CHF; (iv) there are significant between‐
region differences in both the clinical characteristics of HF patients and their outcomes. 
One‐year outcomes 
All‐cause mortality among AHF patients is high, with 4.9% dying during the index 
hospitalization and 23.6% within 1 year. These rates are higher than in the ESC HF Pilot Survey, 
in which the 1‐year all‐cause mortality rate was 17.4%. This increase does not seem to have 
resulted from more countries and regions being included in the ESC‐HF‐LT‐R than in the Pilot 
Survey, because all‐cause death rates were higher than 21% in all regions (and in all countries), 
whereas in the Pilot Survey this figure was exceeded only in the Southern region of that study 
(Greece, Italy, and Spain). Over half of all deaths were of cardiovascular origin. 
 
Unlike the death rate, the 1‐year rate of rehospitalization for HF was lower in this study than in 
the Pilot Survey (22.2% vs. 43.9%). However, this fall was insufficient to prevent the incidence of 
the combined event of death or HF hospitalization being higher in the present study, with 40.1% 
compared with 35.8% in the Pilot Survey.
10
 Thus, improvement in the management of HF patients 
who need hospitalization is urgently needed.  
 
The predictors of all‐cause mortality among AHF patients in this study were similar to those 
found in previous studies, in which older age, lower blood pressure, hepatic or renal dysfunction, 
previous stroke, diabetes, COPD, aortic stenosis, lower EF, and pulmonary or peripheral 
congestion were all predictive of an adverse outcome.
6,10,12-15
 These observations reinforce 
recommendations that patients only be discharged when signs of congestion have completely 
resolved.  
 
Unexpectedly, an ischaemic aetiology was found to be more favourable for AHF patients than 
a non‐ischaemic aetiology. This finding needs further investigation. 
 
Although there were numerous between‐region differences in AHF patient characteristics, the 
only region with a risk of all‐cause death differing significantly from that of the reference region 
(Southern region) was North Africa. The higher risk in this region may be related to North African 
AHF patients being younger and having higher heart rates, and to the less frequent use of beta‐
blockers, ACEI/ARBs and ICDs in that region. 
 
The mortality of CHF patients was significantly lower than that of AHF patients, and a little 
lower than was observed in the Pilot Survey (6.4% vs. 7.2%). Overall, nearly 50% of all deaths 
were of cardiovascular origin. The incidence of the combined endpoint of all‐cause death or 
hospitalization because of HF was a little lower than in the Pilot Survey (14.5% vs. 17.6%).
10
 
 
As in the case of AHF, the predictors of death for CHF patients were similar to those observed 
in previous studies: older age, lower SBP, lower body weight, pulmonary or peripheral congestion, 
aortic stenosis, atrial fibrillation, diabetes, peripheral artery disease, and renal dysfunction.
10,16
 
These observations highlight the need to treat congestion intensively in CHF patients as well as in 
AHF patients; signs of congestion were found in 74.4% of the CHF patients.   
Despite between‐region differences, in many respects the only region with a risk of all‐cause 
death differing significantly from that of the reference region was Northern Europe, where the risk 
was lower. No baseline characteristics were identified that might explain this difference. The 
relatively high P‐value of 0.02 suggests the possibility of a type 1 statistical error, especially as the 
numbers of outpatients and countries in Northern Europe (435 and 2, respectively) were 
considerably smaller than those in Southern region (4321 and 9). There nevertheless appears to be 
an opportunity for further fruitful research here.  
Pharmacological therapy at baseline and 1 year later 
The frequency of prescription of guideline‐recommended medications for CHF patients 
(ACEI/ARBs, beta‐blockers, and MRAs) was quite high, and its maintenance at 1 year follow‐up 
indicates excellent adherence of patients to disease‐modifying therapies. However, it must be 
borne in mind that these patients were probably enrolled in selected centres with extensive 
experience in the field of HF. 
Differences between regions 
The substantial between‐region differences in demographic characteristics and therapeutic 
practices, the latter of which are in keeping with the significant differences in HF management 
organization between different ESC countries (especially between developed and developing 
countries),
17
 may partly explain differences in patient outcomes such as the relatively low 
mortality rates of Southern and Eastern Europe, which are similar to those recently observed in 
Italy.
18
 
 
With regard to the results for North Africa, where the study group was younger and contained a 
larger proportion of women than elsewhere, higher death rates among both AHF and CHF patients 
may be attributable in part to the very much less frequent use of guideline‐recommended medical 
therapies for HF with reduced EF (e.g. ACEI/ARB, beta‐blockers, ICD, and CRT), a shortcoming 
shared by other low‐ and middle‐income countries.19. Alternatively, higher mortality rates in AHF 
may simply reflect differences in the criteria for admission to hospital, such as were observed in a 
recent clinical trial.
20
 Either way, better strategies for HF management are clearly needed in these 
countries. In contrast, it is tempting to speculate that the low rate of hospitalization for HF in 
Northern Europe may result from greater availability of HF disease management programmes, 
especially those with nursing staff involvement.
21-23
 
 
The wide between‐region differences in the use of implantable devices (ICDs and CRTs), 
which for ICDs ranges from 0.2% of patients in North Africa to 21.3% in Western Europe, 
possibly have multifactorial causes involving patient characteristics, resource availability, and 
reimbursement structures. 
 
Several substudies of the ESC‐HF‐LT‐R are currently underway, including specific analyses of 
AHF, atrial fibrillation, BMI, anaemia, kidney disease, or reduced vs. preserved EF, among others. 
  
Limitations 
It must be acknowledged that this study has some important limitations. First, although the 
criteria for HF are well established in the ESC Guidelines,
2
 cases included in the ESC‐HF‐LT‐R 
are diagnosed by local physicians and are not validated centrally. Second, even though consecutive 
enrolment is required by the Registry protocol, we cannot guarantee that this requirement is 
actually respected in all centres; indeed, doubts in this regard are raised by observed differences in 
HF patient numbers between centres of similar overall volume. Third, although it was required that 
centres be selected taking into account the population of the country in which they are located, 
their technological level, resources, and geography, representativeness is always an issue in 
observational studies. Fourth, patients are enrolled only from among those admitted to cardiology 
wards or seen in cardiology outpatient clinics, thus not considering HF patients seen in other units, 
such as emergency or internal medicine services (this may have contributed to the relatively low 
prevalence of HF with preserved EF). Fifth, there is no central committee for the establishment of 
causes of death, and in this study there were a significant number of deaths of unknown cause. 
Last, but not least, several major European countries, including Germany and the UK, did not 
contribute to the ESC‐HF‐LT‐R.  
Conclusions 
The ESC‐HF‐LT‐R has overcome at least some of the limitations of previous HF registries, 
creating a large network of centres and countries that, it is hoped, are representative of the region 
served by the ESC. The results of the present study, in comparison with those of previous studies, 
show that 1‐year mortality is still high among AHF patients but has fallen slightly among CHF 
patients; this difference in trend may reflect, on the one hand the absence of new therapies for 
AHF in recent years, and on the other the increasing use of therapies shown to improve survival 
among CHF patients. Significant between‐region differences in 1‐year outcomes may result from 
major differences in the severity of HF and in therapy, these being attributable to differences in 
medical practices, available resources, and health system structure. The ESC‐HF‐LT‐R provides 
an opportunity for better awareness of the management and outcomes of patients with HF, and for 
the identification of areas for improvement. 
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